Related Experiment Video
Updated: Jun 17, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy
Oliver Schildgen1, Cynthia Olotu, Anneke Funk
1Institut für Pathologie, Kliniken der Stadt Köln, Cologne, Germany.
Abstract:
Recently, we reported on three patients with chronic hepatitis B virus (HBV) infection for whom adefovir (ADF) therapy virologically failed, most likely due to a preexisting rtI233V HBV polymerase mutation. Here, we describe two further patients with chronic HBV infection who were found to develop the rtI233V mutation after initiation of ADF therapy. These patients represent the first cases known so far in which the rtI233V ADF resistance mutation evolved under persistent HBV replication during HBV therapy with ADF. Interestingly, one of the previously described patients, who was initially successfully switched from ADF to tenofovir (TDF) and became virologically suppressed subsequently, experienced a moderate but remarkable rebound of HBV viremia after switching from TDF to entecavir, due to the emergence of renal toxicity. Thus, we provide evidence for the selection and counterselection of the rtI233V ADF resistance mutation during antiviral therapy.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles
Viral Mutations
Inhibitors of Viral Protein Synthesis
Retroviruses
Inhibitors Of Virion Release

